Primary prevention of hepatocellular carcinoma in developing countries

Mutation Research - Reviews in Mutation Research

Volumn 462, Issue 2-3, 2000, Pages 381-393

  Wild, Christopher P ^a   Hall, Andrew J ^b  

^a The Medical School   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Aflatoxins; Chemoprevention; Hepatitis viruses; Hepatocellular carcinoma; Prevention

Indexed keywords

AFLATOXIN; ALUMINOSILICATE CALCIUM; HEPATITIS B VACCINE; HEPATITIS C VACCINE; OLTIPRAZ;

CANCER PREVENTION; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; HEPATITIS B; HEPATITIS C; LIVER CELL CARCINOMA; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS HEPATITIS;

ANIMALIA; FUNGI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; ZEA MAYS;

EID: 0034113808     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(00)00027-2     Document Type: Article

References (82)

1. Parkin D.M. The global burden of cancer. Semin. Cancer Biol. 8:1998;219-235.
2. IARC Hepatitis viruses, monographs on the evaluation of carcinogenic risks to humans. IARC Sci. Publ. 59:1994;. Lyon, France.
3. A.J. Hall, C.P. Wild, Epidemiology of aflatoxin related disease, in: D.A. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance, Academic Press, 1994, pp. 233-258.
4. IARC IARC monographs on the evaluation of carcinogenic risks to humans some naturally occuring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. IARC Sci. Publ. 56:1993;. Lyon, France.
5. Parkin D.M., Pisani P., Munoz N., Ferlay J. The global health burden of infection associated cancers. Cancer Surv. 33:1999;5-33.
6. Montesano R., Hainaut P., Wild C.P. Hepatocellular carcinoma: from gene to public health. JNCI. 89:1997;1844-1851.
7. Qian G.S., Ross R.K., Yu M.C., Yuan J.M., Gao Y.T., Henderson B.E., Wogan G.N., Groopman J.D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol., Biomarkers Prev. 3:1994;3-10.
8. Wild C.P., Hall A.J. Hepatitis B virus and liver cancer: unanswered questions. Cancer Surv. 33:1999;35-54.
9. Taiwan Childhood Hepatoma Study Group, Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., Chen D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336:1997;1855-1859.
10. Edmunds W.J., Medley G.F., Nokes D.J., Hall A.J., Whittle H.C. The influence of age on the development of the hepatitis B carrier state. Proc. R. Soc. London, Biol. 253:1993;197-201.
11. Barin F., Perrin J., Chotard J., Denis F., N'Doye R., Diop Mar I., Chiron J.P., Coursaget P., Goudeau A., Maupas P. Cross sectional and longitudinal epidemiology of hepatitis B in Senegal. Prog. Med. Virol. 27:1981;148-162.
12. Fortuin M., Chotard J., Jack A.D., Maine N.P., Mendy M., Hall A.J., Inskip H.M., George M.O., Whittle H.C. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet. 341:1993;1129-1131.
13. S. Viviani, A.D. Jack, A.J. Hall, N. Maine, M. Mendy, R. Montesano, H.C. Whittle, Hepatitis B vaccine efficacy at nine years of age following infant vaccination in The Gambia, Vaccine, 1999, in press.
14. Hall A.J., Robertson R.L., Crivelli P.E., Lowe Y., Inskip H., Snow S.K., Whittle H. Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans. R. Soc. Trop. Med. Hyg. 87:1993;333-336.
15. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology. 26:1997;15S-20S.
16. Alter M.J. Epidemiology of hepatitis C. Eur. J. Gastroenterol. Hepatol. 8:1996;319-323.
17. Jelinek C.F., Pohland A.E., Wood G.E. Worldwide occurrence of mycotoxins in foods and feeds - an update. J. Assoc. Anal. Chem. 72:1989;223-230.
18. Beardall J., Miller J.D. Natural occurrence of mycotoxins other than aflatoxin in Africa, Asia and South America. Mycotoxin Res. 10:1994;21-40.
19. CAST, Mycotoxins: economic and health risks. Council for Agricultural Science and Technology Ames IA 50010, 1989.
20. C.P. Wild, A.J. Hall, Epidemiology of mycotoxin-related disease, in: H. Howard, J.D. Miller (Eds.), The Mycota VI. Human and Animal Relationships, Springer-Verlag. Berlin, Heidelberg, 1996, pp. 213-227.
21. van Egmond H.P. Mycotoxins: regulations, quality assurance and reference materials. Food Addit. Contam. 12:1995;321-330.
22. Wang L.Y., Hatch M., Chen C.J., Levin B., You S.L., Lu S.N., Wu M.H., Wu W.P., Wang L.W., Wang Q., Huang G.T., Yang P.M., Lee H.S., Santella R.M. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer. 67:1996;620-625.
23. Denning D.W. Aflatoxin and human disease. Adverse Drug React. Acute Poisoning Rev. 6:1987;175-209.
24. J.J. Pestka, G.S. Bondy, Mycotoxin-induced immune modulation, in: J.H. Dean, M.I. Luster, A.E. Munson, I. Kimber, (Eds.), Immunotoxicology and Immunopharmacology, Raven Press, New York, 1994, pp. 163-182.
25. Campbell T.C., Caedo J.P. Jr., Bulatao-Jayme J., Salamat L., Engel R.W. Aflatoxin M1 in human urine. Nature. 227:1970;403-404.
26. IARC/IPCS Working Group, Development and Possible Use of Immunological Techniques to Detect Individual Exposure to Carcinogens, IARC Internal Techn. Rep. 82/001 (1982) 25.
27. Wild C.P., Umbenhauer D., Chapot B., Montesano R. Monitoring of individual human exposure to Aflatoxins (AF) and N-Nitrosamines (NNO) by immunoassays. J. Cell. Biochem. 30:1986;171-179.
28. Sizaret P., Malaveille C., Montesano R., Frayssinet C. Detection of aflatoxins and related metabolites by radioimmunoassay. JNCI. 69:1982;1375-1381.
29. Groopman J.D., Donahue P.R., Zhu J.Q., Chen J.S., Wogan G.N. Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc. Natl. Acad. Sci. USA. 82:1985;6492-6496.
30. Zhu J.Q., Zhang L.S., Hu X., Xiao Y., Chen J.S., Xu Y.C., Fremy J., Chu F.S. Correlation of dietary aflatoxin B1 levels with excretion of aflatoxin M1 in human urine. Cancer Res. 47:1987;1848-1852.
31. Sabbioni G., Skipper P.L., Buchi G., Tannenbaum S.R. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis. 8:1987;819-824.
32. Wild C.P., Garner R.C., Montesano R., Tursi F. Aflatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis. 7:1986;853-858.
33. Wild C.P., Jiang Y.Z., Sabbioni G., Chapot B., Montesano R. Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. Cancer Res. 50:1990;245-251.
34. Sabbioni G., Ambs S., Wogan G.N., Groopman J.D. The aflatoxin-lysine adduct quantified by high-performance liquid chromatography from human serum albumin samples. Carcinogenesis. 11:1990;2063-2066.
35. Gan L.S., Skipper P.L., Peng X., Groopman J.D., Chen J.S., Wogan G.N., Tannenbaum S.R. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis. Correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. Carcinogenesis. 9:1988;1323-1325.
36. Wild C.P., Jiang Y.Z., Allen S.J., Jansen L.A.M., Hall A.J., Montesano R. Aflatoxin-albumin adducts in human sera from different regions of the world. Carcinogenesis. 11:1990;2271-2274.
37. Ross R.K., Yuan J.M., Yu M.C., Wogan G.N., Qian G.S., Tu J.T., Groopman J.D., Gao Y.T., Henderson B.E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 339:1992;943-946.
38. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 350:1991;429-431.
39. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:1991;427-428.
40. G. Kirk, A.M. Camus-Randon, J. Goedert, P. Hainaut, R. Montesano, p53 mutation in sera of patients with hepatocellular carcinoma and cirrhosis in The Gambia (West Africa) [Abstract], AACR 90th Annual Meeting, Vol. 40, 1999, p. 41.
41. Kensler T.W., Groopmam J.D., Sutter T.R., Curphey T.J., Roebuck B.D. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem. Res. Toxicol. 12:1999;113-126.
42. Kensler T.W., Gange S.J., Egner P.A., Dolan P.M., Munoz A., Groopman J.D., Rogers A.E., Roebuck B.D. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol. Biomarkers Prev. 6:1997;603-610.
43. Hill R.A., Blankenship P.D., Cole R.J., Sanders T.H. Effects of soil moisture and temperature on preharvest invasion of peanuts by the Aspergillus flavus group and subsequent aflatoxin development. Appl. Environ. Microbiol. 45:1983;628-633.
44. J.I. Keenan, G.P. Savage, Mycotoxins in groundnuts, with special reference to aflatoxin, in: J. Smartt (Ed.), The Groundnut Crop: A Scientific Basis for Improvement, Chapman and Hall, London, 1994, pp. 509-551.
45. N. Lisker, E.B. Lillehoj, Prevention of mycotoxin contamination (principally aflatoxins and Fusarium toxins) at the preharvest stage, in: J.E. Smith, R.S. Henderson (Eds.), Mycotoxins and Animal Foods, CRC Press, Boca Raton, FL, 1991, pp. 689-719.
46. D'Mello J.P.F., Macdonald A.M.C., Postel D., Dijksma W.T.P., Dujardin A., Placinta C.M. Pesticide use and mycotoxin production in Fusarium and Apergillus phytopathogens. Eur. J. Plant Pathol. 104:1998;741-751.
47. P.J. Cotty, P. Bayman, D.S. Egel, K.S. Elias, Agriculture, Aflatoxins and Aspergillus, in: K.A. Powell et al. (Eds.), The Genus Aspergillus, Plenum, New York, 1994, pp. 1-27.
48. D. Bhatnagar, P.J. Cotty, T.E. Cleveland, Preharvest aflatoxin contamination molecular strategies for its control, Food Flavor and Safety, American Chemical Society (1993) 272-292.
49. Dorner J.W., Cole R.J., Wicklow D.T. Aflatoxin reduction in corn through field application of competitive fungi. J. Food Prot. 62:1999;650-656.
50. Brown R.L., Chen Z.Y., Cleveland T.E., Russin J.S. Advances in the development of host resistance in corn to aflatoxin contamination by Aspergillus flavus. Phytopathology. 89:1999;113-117.
51. Dorner J.W., Cole R.J., Blankenship P.D. Effect of inoculum rate of biological control agents on preharvest ctamination of peanuts. Biol. Control. 12:1998;171-176.
52. Horn B.W., Dorner J.W. Regional differences in production of aflatoxin B1 and cyclopiazonic acid by soil isolates of Apergillus flavus along a transect within the United States. Appl. Environ. Microbiol. 65:1999;1444-1449.
53. Wambugu F. Why Africa needs agricultural biotechnology. Nature. 400:1999;15-16.
54. D. Bhatnagar, T.E. Cleveland, P.J. Cotty, Mycological aspects of aflatoxin formation, in: D.L. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance, Academic Press, 1994, pp. 327-346.
55. Bhatnagar D., Cleveland T., Linz J., Payne G. Molecular biology to eliminate aflatoxins. INFORM. 6:1995;262-271.
56. Mehan V.K., McDonald D., Ramakrishna N. Varietal resistance of peanuts to aflatoxin production. Peanut Sci. 13:1986;7-10.
57. Payne G.A. Aflatoxin in maize. Crit. Rev. Plant Sci. 10:1992;423-440.
58. Ehrlich K.C., Montalbano B.G., Bhatnagar D., Cleveland T.E. Alteration of different domains in AFLR affects aflatoxin pathway metabolism in Aspergillus parasiticus transformants. Fungal Genet. Biol. 23:1998;279-287.
59. Chen Z.Y., Brown R.L., Lax A.R., Guo B.Z., Cleveland T.E., Russin J.S. Resistance to Aspergillus flavus in corn kernels is associated with a 14-kDa protein. Phytopathology. 88:1998;276-281.
60. Huang Z., White D.G., Payne G. Corn seed proteins inhibitory to Aspergillus flavus and aflatoxin biosynthesis. Phytopathology. 87:1997;622-627.
61. Guo B.Z., Brown R.L., Lax A.R., Cleveland T.E., Russin J.S., Widstrom N.W. Protein profiles and antifungal activities of kernel extracts from corn genotypes resistant and susceptible to Aspergillus flavus. J. Food Prot. 61:1998;98-102.
62. Crompton J.A.F., Tyler P.S., Hindmarsh P.S., Golob P., Boxall R.A., Haines C.P. Reducing losses in small farm grain storage in the tropics. Trop. Sci. 33:1993;283-318.
63. Karlovsky P. Biological detoxification of fungal toxins and its use in plant breeding, feed and food production. Nat. Toxins. 7:1999;1-23.
64. T.D. Phillips, B.A. Clement, D.L. Park, Approaches to reduction of aflatoxins in foods and feeds, in: D.A. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance, Academic Press, 1994, pp. 383-406.
65. Franzolin M.R., Gambale W., Cuero R.G., Correa B. Interaction between toxigenic Aspergillus flavus link and mites (Tyrophagus puterscentiae schrank) on maize grains: effects on fungal growth and aflatoxin production. J. Stored Prod. Res. 35:1999;215-224.
66. Dickens J.W., Whitaker T.B. Efficacy of electronic color sorting and hand picking to remove aflatoxin contaminated kernels from contaminated lots of shelled peanuts. Peanut Sci. 2:1975;45-50.
67. Shantha T., Sreenivasa M., Rati E.R., Prema V. Detoxification of groundnut seeds by urea and sunlight. J. Food Safety. 7:1986;225-232.
68. Yu S.Z. Primary prevention of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 10:1995;674-682.
69. Njapau H., Muzungaile E.M., Changa R.C. The effect of village processing techniques on the content of aflatoxins in corn and peanuts in Zambi. J. Sci. Food Agri. 76:1998;450-456.
70. D.A. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance, Academic Press, 1994.
71. Wild C.P., Hasegawa R., Barraud L., Chutimataewin S., Chapot B., Ito N., Montesano R. Aflatoxin albumin adducts - a basis for comparative carcinogenesis between animals and humans. Cancer Epidemiol. Biomarkers Prev. 5:1996;179-189.
72. Gorelick N.J. Risk assessment for aflatoxin: I. Metabolism of aflatoxin B1 by different species. Risk Anal. 10:1990;539-559.
73. Judah D.J., Hayes J.D., Yang J.C., Lian L.Y., Roberts G.C., Farmer P.B., Lamb J.H., Neal G.E. A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1 is expressed in rat liver during carcinogenesis and following the administration of an anti-oxidant. Biochem. J. 292:1993;13-18.
74. Egner P.A., Gange S.J., Dolan P.M., Groopman J.D., Munoz A., Kensler T.W. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis. 16:1995;1769-1773.
75. Roebuck B.D., Liu Y.L., Rogers A.E., Groopman J.D., Kensler T.W. Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res. 51:1991;5501-5506.
76. Wang J.S., Shen X., He X., Zhu Y.R., Zhang B.C., Wang J.B., Qian G.S., Kuang S.Y., Zarba A., Egner P.A.et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. JNCI. 91:1999;347-354.
77. Kensler T.W., He X., Otieno M., Egner P.A., Jacobson L.P., Chen B., Wang J.S., Zhu Y.R., Zhang B.C.et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev. 7:1998;127-134.
78. Wang J.S., Qian G.S., Zarba A., He X., Zhu Y.R., Zhang B.C., Jacobson L., Gange S.J., Munoz A., Kensler T.W.et al. Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 5:1996;253-261.
79. Jacobson L., Zhang B.C., Zhu Y.R., Wang J.B., Wu Y., Zhang Q.N., Yu L.Y., Qian G.S., Kuang S.Y., Li Y.F.et al. Oltipraz intervention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol. Biomarkers Prev. 6:1996;257-265.
80. Abdel-Wahhab M.A., Nada S.A., Amra H.A. Effect of aluminosilicates and bentonite on aflatoxin-induced developmental toxicity in rat. J. Appl. Toxicol. 19:1999;199-204.
81. Dashwood R., Negishi T., Hayatsu H., Breinholt V., Hendricks J., Bailey G. Chemopreventive properties of chlorophylls towards aflatoxin B1: a review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat. Res. 399:1998;245-253.
82. Chen H.L., Chang M.W., Ni Y.H.et al. Seroepidemiology of hepatitis B virus infection in children. Ten years of mass vaccination in Taiwan. JAMA. 276:1996;906-908.